XML 60 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727
REVENUES (Tables)
3 Months Ended
Mar. 31, 2015
Revenues [Abstract]  
Schedule Of Recognized Net Sales [Table Text Block]
A summary of recognized net sales for the three months ended March 31, 2015 and ending net deferred sales as of March 31, 2015 for the company’s two FDA-approved products as of March 31, 2015 is presented below:
 
 
 
 
 
 
 
Deferred Sales
 
 
 
 
 
 
 
 
 
reclassed against
 
Ending Deferred
 
 
 
Sales Recognized in
 
 
 
outstanding
 
Sales for which
 
Quarter ended March 31, 2015
 
the Current Period
 
Deferred
 
Accounts
 
Payment has been
 
($ in thousands)
 
(Branded Only)
 
Sales
 
Receivable
 
Collected
 
Gross Sales
 
$
74,480
 
$
35,797
 
$
(31,954)
 
$
3,843
 
Less:
 
 
 
 
 
 
 
 
 
 
 
 
 
Chargebacks
 
 
31,944
 
 
-
 
 
-
 
 
-
 
Wholesaler distribution fees
 
 
6,779
 
 
2,946
 
 
(2,659)
 
 
287
 
Cash discounts and other
 
 
1,491
 
 
716
 
 
(639)
 
 
77
 
GPO fees and returns
 
 
2,098
 
 
-
 
 
-
 
 
-
 
Net Sales
 
$
32,168
 
$
32,135
 
$
(28,656)
 
$
3,479
 
Schedule Of Changes In Reserve Or Liability [Table Text Block]
A summary of changes for each reserve or liability for Bloxiverz®, Vazculep and the company’s generic pharmaceutical product for the three month period ended March 31, 2015 is as follows:
 
Quarter ended March 31, 2015
 
 
 
 
 
 
 
Ending
 
($ in thousands)
 
Beginning Balance
 
Additions
 
Reductions
 
Balance
 
Accounts Receivable Reserves:
 
 
 
 
 
 
 
 
 
 
 
 
 
Chargebacks
 
$
1,008
 
$
37,290
 
$
(35,116)
 
$
3,182
 
Wholesaler distribution fees
 
 
1,079
 
 
4,185
 
 
(3,311)
 
 
1,953
 
Cash Discounts and other
 
 
252
 
 
2,265
 
 
(1,915)
 
 
602
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
GPO fees
 
 
112
 
 
1,083
 
 
(112)
 
 
1,083
 
Sales returns
 
 
234
 
 
2,812
 
 
(1,801)
 
 
1,245
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
$
2,686
 
$
47,635
 
$
(42,256)
 
$
8,065